The Latest Breaking News from Pfizer

The efficacy of third doses of the Pfizer and Moderna mRNA vaccines wanes substantially by the fourth month after administration, a new study by the US Centers of Disease Control and Prevention (CDC) said Friday. Though it's now well documented that vaccine efficacy goes down after two doses, relatively little…

China on Saturday said it had given "conditional" approval for Pfizer's Covid-19 drug Paxlovid to treat adults with mild to moderate illness and a high risk of developing severe disease. The drug has so far been authorized in about 40 countries including the United States and Israel, while the European…

The second booster with Pfizer or Moderna raises antibodies but not enough to protect against the Omicron Covid-19 variant. 

U.S. health officials postponed a meeting of advisers on Pfizer Inc.’s COVID-19 vaccine for children under age 5, after the drugmaker said it has new data to add to its application for clearance.

U.S. regulators have put the brakes on their push to speed Pfizer’s COVID-19 to children under 5

Company says it will now not have data on third dose protection until April

The companies said they will wait for more data on three doses for children under 5.

The FDA postponed a Feb. 15 review of the Pfizer shots for young children ages 6 months to 4 years old, citing the need for more time.

Drug behemoth Pfizer was the first to launch a Covid antiviral pill — but a pack of small biotech stocks are already nipping at its heels.